Latest News and Press Releases

Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.

Ottawa, May 22, 2024 (GLOBE NEWSWIRE) -- The global alopecia areata market size was valued at USD 3.09 billion in 2023 and is predicted to hit around USD 5.68 billion by 2031, a study published by...

Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...

San Rafael, CA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- For anyone living with or touched by alopecia areata, you do not have to walk alone!  The National Alopecia Areata Foundation is holding its first...

Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...

ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...

PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...

PARAMUS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their...

Los Angeles, USA, March 23, 2021 (GLOBE NEWSWIRE) -- Alopecia Areata Clinical Trials Report: Pipeline Insight 2021 by DelveInsight The increasing R&D investments for strong Alopecia Areata...

Rising incidences of chronic disorders such as hyperthyroidism, acute stress disorder hypopituitarism, hypothyroidism, and lupus are the major factors influencing market growth. Market Size – USD...